1. United States
2. Nev.
3. Letter

I am writing to address the critical shortage of medications for treating attention deficit hyperactivity disorder (ADHD), particularly Adderall. This shortage has been caused by a combination of factors including limited production quotas set by the Drug Enforcement Administration, overprescription and increasing demand, as well as supply chain issues. The impacts of this shortage are severe for millions of Americans who rely on these medications to manage their ADHD symptoms and function in daily life. Without access to proper treatment, individuals with ADHD may experience difficulties with focus, organization, impulse control, and emotional regulation—all of which can profoundly disrupt academic performance, workplace productivity, and overall wellbeing. While the root causes are multifaceted, decisive action is needed to increase production of ADHD medications and secure stable supply chains to meet the treatment needs of this population. One critical step is adjusting DEA quotas to align with current clinical demands. Additionally, strategies should be explored to incentivize pharmaceutical companies to ramp up manufacturing of these medications which tend to have lower profit margins. Improving access to ADHD medications is not only a matter of ensuring effective treatment, but also of promoting equity and supporting the ability of individuals to reach their full potential across all spheres of life. I urge you to make this a policy priority and work towards sustainable solutions to prevent future disruptions to this essential treatment. The impacts reverberate through communities, households, classrooms and workplaces—we cannot afford inaction.